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Background: Here we investigated Brahma-related gene 1 (BRG1) expression in aortic smooth muscle cells (SMCs)
and its role in the regulation of the pathological changes in aortic SMCs of thoracic arotic dissection (TAD).
Methods: BRG1, matrix metalloproteinase 2 (MMP2), and MMP9 mRNA and protein expression in human aortic
specimens were examined by qPCR and western blot, respectively. The percentage of apoptotic and contractile
SMCs in aortic specimens were determined by TUNEL assay and α-SMA immunohistochemical staining, respectively.
The role of BRG1 in MMP2 and MMP9 expression, cell apoptosis, and phenotype transition in aortic SMCs were
investigated using a human aortic SMC line via adenovirus mediated gene transfer. MMPs mRNA and protein
levels were analyzed by qPCR and western blot, respectively. The percentage of apoptotic and contractile cells
were determined through flow cytometry analysis.
Results: The expression level of BRG1 in the aortic walls (adventitia-removed) was significantly higher in the TAD
than the normal group. BRG1 expression was positively correlated to expression of MMP2 and MMP9 and SMC
apoptosis, but was negatively correlated to the percentage of contractile aortic SMCs in TAD specimens. In human
aortic SMC line, BRG1 transfection led to significant upregulation of MMP2 and MMP9 expression and a
concomitant increase in SMC apoptosis as well as a decrease in the percentage of contractile phenotype of cells.
Conclusions: BRG1 is significantly upregulated in the aortic SMCs of TAD, and its overexpression might promote
the development of TAD by increasing MMP2 and MMP9 expression, inducing SMC apoptosis and the transition
from contractile to synthetic phenotype.
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Thoracic aortic dissection (TAD) is a life-threatening
aortic catastrophe with high mortality [1-3]. It was
reported that approximately 70% of untreated TAD cases
would die during the first week following the occurrence
of dissection [1-3]. The normal aortic media is mainly
composed of concentrically arranged vascular smooth
muscle cells (SMCs) and extracellular matrix (ECM) rich
in elastic fibers, and the interplay between SMCs and
ECM plays an important role for the structural and* Correspondence: zhiyunxu@gmail.com; huangsd@smmu.edu.cn
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unless otherwise stated.functional integrity of the aortic wall [4,5]. Previous studies
showed that overexpression of matrix metalloproteinase
2 (MMP2) and MMP9 in aortic SMCs might induce
extracellular matrix degradation, apoptosis and phenotypic
transition from the contractile to the synthetic type and
that such pathological changes might result in instability of
the aortic media, which are responsible for the occurrence
of TAD [6-10]. It was reported that single gene mutation
may cause aortic SMC dysfunction leading to the
development of TAD [11,12]. Over 80% of TAD cases,
however, were found to be sporadic [5], suggesting
that aortic SMC dysfunction may be mainly attributable
to abnormal gene expression.
Brahma-related gene 1 (BRG1) is an ATPase subunit
of the SWI/SNF complex, which is required for thed. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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chromatin remodeling [13,14]. Previous studies showed
that BRG1 plays an important role in the proliferation
and differentiation of vascular cells [15-17]. Recently, it
was found that BRG1 overexpression could induce cell
apoptosis in rat mesenchymal stem cells and some
human tumor cells [18-20]. Besides, it was reported
that BRG1 could promote MMP2 and MMP9 expression
in some human tumor cells [21,22]. However, it is unclear
whether BRG1 is involved in the regulation of MMP
(especially MMP2 and MMP9) expression, apoptosis and
phenotypic transition in aortic SMC during development
of TAD.
In light of previous studies, we hypothesized that
abnormal expression of BRG1 in aortic SMC might
be involved in the development of TAD. To test the
hypothesis, we investigated BRG1 expression in aortic
SMCs of TAD and explored its role in the pathological
processes of TAD. In clinical samples of TAD, BRG1
expression is significantly increased in aortic SMCs of TAD
as compared with the controls. Moreover, the expression
level of BRG1 was positively correlated with MMP2 and
MMP9 expression and apoptosis index, but was negatively
correlated with the proportion of contractile aortic SMCs
in the aortic media of TAD. In a human aortic SMC line,
we demonstrated that BRG1 overexpression markedly
enhanced the expression of MMP2 and MMP9 and
promoted apoptosis and the transition from the contractile
to the synthetic phenotype. Our data suggest that
BRG1 overexpression in aortic SMCs may be involved




Aortic dissection specimens were obtained from 30 patients
of acute type A TAD who underwent aortic replacement
procedures at Changhai hospital in 2011. Aortic tissues
from patients with hereditary connective tissue defects,
such as Marfan’s syndrome, traumatic aneurysms or luetic
aortic aneurysms were excluded. Control aortic specimens
were obtained from 12 donors. The subjects with TADs
and controls showed no significantly difference in clinical
features including age, gender, smoking status, hypertension
or diabetes. During surgery, full-thickness aortic wall
specimens were collected from patients who underwent
surgical repair of TAD (ascending aortas above the sinuses
of Valsalva). Control specimens from normal ascending
aortas were obtained from 12 organ donors. The aortic
tissue was carefully cleared of adventitia, fixed in formalin
for immunohistochemical staining or frozen fresh for
Western blot analysis and qPCR.
The present study was conducted in accordance with
the World Medical Association Declaration of Helsinkiand was approved by the Medical Ethics Committee
of Changhai Hospital. All participants signed informed
consents.
Cell culture
Human aortic SMCs (smooth muscle cells) line from
healthy aortas was obtained from Cascade Biologics
and was used up to passage 8. The cells were cultured
according to supplier’s instructions, and were grown in
Medium 231 with smooth muscle growth supplements
(Cascade Biologics).
Adenovirus mediated cell infection
Ad.BRG1 and Ad.Null were constructed using AdEasy
system (Stratagene) according to user protocol. Human
SMCs were infected with Ad.BRG1 or Ad.Null using a
multiplicity of infection of 1:100 for 12 h at 37°C before
further examination.
Immunohistochemistry
Sections (5 μm) of the specimens were incubated with
mouse anti-human primary antibodies (i.e. anti-BRG1,
α-SMA, MMP2 and MMP9, Santa Cruz) overnight at
4°C, followed by incubation with horseradish peroxidase-
conjugated goat anti-mouse antibody (Santa Cruz) for
1 hr at 37°C. Immunodetection was performed with the
EnVisionTM Kit (Dako), using diaminobenzidine as the
chromogen.
TUNEL staining
The TUNEL reaction was performed with an in situ cell
detection kit (Roche Applied Science, Indianapolis,
IN, USA), according to the manufacturer’s instruction, to
detect the apoptosis of media cells. TUNEL-positive nuclei
(stained brown) were counted by Motic Images Advanced
3.2 in 10 random fields (×200), and then averaged.
Apoptosis assay
Cell apoptosis was analyzed by annexin V-FITC assay.
Briefly, cells were stained with annexin V-FITC and
propidium iodide using the ANNEXIN V-FITC Kit
(Beckman) according to the manufacturer’s protocol
and subjected to flow cytometric analysis. Viable cells were
not stained by annexin V or propidium iodide; early
apoptotic cells were stained by annexin V but not propidium
iodide whilst late apoptotic cells were stained by annexin
V and propidium iodide.
Protein extraction and Western blot analysis
For protein extraction, the tissue or cell samples were
harvested in hypotonic lysis buffer (10 mM Tris–HCl,
pH 7.5, 10 mM NaCl, 0.2 mM EDTA, 1 mM DTT)
supplemented with inhibitors (25 mM b glycerol-
phosphate, 25 mM NaF, 1 mM Na3VO4, 1 mM PMSF,
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homogenisation and centrifuged at 500 g for 5 min to
eliminate nuclei and debris. The supernatant was subjected
to ultracentrifugation at 20,000 g for 60 min using the
TLA-100.2 fixed angle rotor in Optima TL-100 ultracentri-
fuge (Beckman). The supernatant (cytoplasm) was adjusted
to 100 mM NaCl and 0.5% Nonidet P-40. The membrane
pellet was resolubilised in NETN buffer (50 mM Tris–HCl,
pH 7.5, 100 mM NaCl, 200 mM EDTA, 0.5% Nonidet
P-40, 1 mM DTT, supplemented with inhibitors).
Equal amounts of protein (50 μg) were separated by
10% SDS PAGE and then transferred to nitrocellulose
membranes (NY, USA) by electroblotting. The membranes
were blocked with 5% BSA in TBST (10 mM Tris–HCl,
pH 8.0, 150 mM NaCl, and 0.05% Tween 20) for 1 hr, and
then incubated with mouse anti-human primary antibodies
at 4°C overnight before subsequent incubation with
horseradish peroxidase-conjugated goat anti-mouse
antibody (BD) for 1 hr at 37°C. Protein was visualized
using enhanced chemiluminescence reagent (Santa Cruz).
The expression level of target protein was analyzed
using LabWork 4.0 program (UVP) and normalized to
that of β-actin protein.
Quantitative reverse transcription polymerase chain
reaction (qRT-PCR)
Total RNA was extracted from 100 mg tissues or 1 × 105
cells using the RNeasy RNA Mini Kit (Qiagen). First strand
cDNA was synthesized using POWERSCRIPT reverse tran-
scriptase (Clontech). The following gene-specific primer
pairs were used for quantitative PCR:
BRG1: Forward, 5′- TCATGTTGGCGAGCTATTTCC -3′;
Reverse, 5′- GGTTCCGAAGTCTCAACGATG-3′.
MMP2: Forward, 5′- TTACTTGTGGAGCCGCTGAC -3′;
Reverse, 5′- TCAGATGGTGCCAGCAATAG -3′.Figure 1 BRG1 expression is upregulated in aortic SMCs of TAD speci
BRG1 in aortic media of TAD and normal aortic tissues. Expression level of
Bar =50 μm. (B, C) The expression of BRG1 mRNA and protein in TAD and no
to that of GAPDH and β-actin, respectively. Each dot represents the relative ex




Reverse, 5′- AGTTGGTGGTGCAGGATGC -3′.
PCR was performed using a Fast Start Master SYBR
Green Kit (Roche) on a LightCycler (Roche). The expression
level of target gene mRNA was analyzed using RealQuant
software (Roche) and normalized to that of GAPDH
mRNA.
Statistical analysis
Statistical significance was tested using SPSS15.0 software.
The correlation between the expressions of two genes was
analyzed using Pearson’s correlation analysis. Other
data are presented as mean ± SEM from 4 independent
experiments, using student t tests for 2-group comparison.
A P value less than 0.05 is considered as statistically
significant.
Results
BRG1 expression is upregulated in aortic SMCs of TAD
specimens
In the present study, we first scanned the expression of
BRG1 in TAD and normal aortic tissues by immunohisto-
chemical analysis. It was found that BRG1 was mainly
localized in the nucleus of aortic SMCs. Expression level
of BRG1 protein was intense in TAD media, whereas it
was low intense in the normal tissue. The number of
BRG1 positive cells was significantly higher in TAD tissues
than in normal aortic tissues (Figure 1A). Through
qRT-PCR and western blot, we further revealed that
the expression level of BRG1 mRNA and protein was
2.8 and 2.0 fold higher in the aortic media of TAD
tissues compared with the normal tissues, respectivelymens. (A) Representative images of immunohistochemical staining for
BRG1 protein was moderate in TAD and was weak in normal tissue.
rmal tissues was detected by qRT-PCR and western blot and normalized
pression level of BRG1 mRNA (B) and protein (C) of a tissue sample
vel; **, P <0.01 by paired t test.
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expression is significantly upregulated in aortic SMCs of
TAD specimens.BRG1 expression is positively correlated to the rate of
apoptotic cells in aortic SMCs of TAD specimens
Apoptosis is one of the mechanisms underlying aortic
medial layer SMC loss. To investigate the effect of BRG1
on apoptosis of aortic SMCs, we analyzed the relationship
between BRG1 expression and the apoptotic rate of aortic
SMCs. As shown in Figure 2A, TUNEL-positive cells were
hardly detectable in normal aortic tissues. In direct con-
trast, TUNEL-positive cells were numerous in the middle
layer of TAD tissues. The number of TUNEL-positive cells
in TAD tissues was significantly higher than that in the
control group. Moreover, it was found that the expression
of BRG1 was significantly positively correlated with the
rate of TUNEL-positive cells in TAD tissues (Figure 2B).BRG1 expression is positively correlated to the expression
of MMP2 and MMP9 in aortic SMCs of TAD specimens
High expression of MMP2 and MMP9 was reported to
contribute to the development of TAD. Consistent with
the previous studies, immunohistochemistry assay showed
that the expressions of MMP2 and MMP9 in TAD tissues
were significantly higher than in the normal tissues
(Figure 3A). To investigate the possible relationship
between BRG1 and MMP2/9 expression, we performed
correlation analysis of the western blot data and found
that expression of BRG1 was significantly positively corre-
lated with the expression of MMP2 (and MMP9) in TAD
tissues (Figure 3B), suggesting that BRG1 might increaseFigure 2 BRG1 expression is positively correlated to the rate of apop
images of TUNEL staining in aortic media of TAD and normal tissues. The p
in normal tissues. Bar =50 μm. (B) Dot plots represent log10percentage of a
represent approximated curves. The correlation coefficient (r) and the P val
between the x and y variables.the expression of MMP2 and MMP9 in aortic SMCs of
TAD specimens.BRG1 expression is negatively correlated to the rate of
contractile SMCs in TAD specimens
Previous studies showed that aortic SMCs transited from
contractile to synthetic phenotype cells led to reduce the
contraction of aortic SMCs and thus weaken the aortic
wall. α-SMA is widely used as a marker of the contractile
phenotype of SMCs. Coinciding with the previous studies,
immunohistochemistry assay showed that the expressions
percentage of α-SMA positive cells in TAD tissues were
significantly lower than that in the normal tissues
(Figure 4A). Moreover, it was found that the expression of
BRG1 was significantly negatively related to the
percentage of α-SMA-positive cells in TAD tissues
(Figure 4B). These data suggest that BRG1 might transit
aortic SMCs from contractile to synthetic phenotype cells
in TAD specimens.Overexpression of BRG1 induces apoptosis of aortic SMCs
To determine the effect of BRG1 on the apoptosis of
human aortic SMCs, the apoptosis of human aortic
SMCs transfected Ad.BRG1 was detected by flow cytome-
try. It was found that the expression of BRG1 mRNA and
protein was significantly increased in the aortic SMCs
treated with Ad.BRG1 as compared to the cells treated with
Ad.Null at 72 hr post-infection (Figure 5A and B). Using
annexin V-FITC assay, we found that in human aortic
SMC line, the percentage of annexin V-FITC+/PI− and
annexin V-FITC+/PI+ in Ad.BRG1 infected cells were both
significantly higher than those in Ad.Null infected cellstotic cells in aortic SMCs of TAD specimens. (A) Representative
ercentage of TUNEL positive cells was significantly higher in TAD than
poptotic cells against log10BRG1 protein expression level. The lines
ue indicate the statistical significance of the positive correlation
Figure 3 BRG1 expression is positively correlated to the expression of MMP2 and MMP9 in aortic SMCs of TAD specimens. (A) Representative
images of immunohistochemical staining for MMP-2 and MMP-9 in aortic media of TAD and normal tissues. Expression level of MMP-2 and MMP-9
protein was significantly higher in TAD than in normal. Bars =50 μm. (B, C) Dot plots represent log10MMP-2 expression (B) and log10MMP-9 expression
(C) against log10BRG1 protein expression level. The lines represent approximated curves. The correlation coefficient (r) and the P value indicate the
statistical significance of the negative correlation between the x and y variables.
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BRG1 promotes apoptosis of human aortic SMCs.
Overexpression of BRG1 increases MMP2 and MMP9
expression in aortic SMCs
To investigate the effect of BRG1 on the MMP2 and
MMP9 expression in aortic SMCs, MMP2 and MMP9
mRNA and protein levels in cultured human aortic SMCs
treated with Ad.BRG1 were analyzed by qPCR and Western
blotting. It was found that the expression of both MMP2
and MMP9 mRNA (or protein) in Ad.BRG1 infected cells
was significantly higher than those in Ad.Null-infected cells
(Figure 6A and B), suggesting that overexpression of BRG1
increases MMP2 and MMP9 expression in aortic SMCs.Figure 4 BRG1 expression is negatively correlated to the rate of cont
immunohistochemical staining for α-SMA in aortic media of TAD and norm
significantly lower than that in the normal tissues. Bars =50 μm. (B) Dot plo
protein expression level. The lines represent approximated curves. The corr
of the negative correlation between the x and y variables.Overexpression of BRG1 promotes transistion of aortic
SMCs from the contractile to the synthetic phenotype
To investigate the effect of BRG1 on the phenotypic
transition of aortic SMCs, the expression of α-SMA was
analyzed by qPCR and western blotting, and percentage
of α-SMA-positive cells was analyzed by flow cytometry
in cultured human aortic SMCs treated with Ad.BRG1. As
shown in Figure 7A and B, the expression of α-SMA
mRNA and protein was significantly lower in
Ad.BRG1-infected cells than in Ad.Null-infected cells.
In addition, the percentage of α-SMA-positively cell
in Ad.BRG1 treated cells was significantly lower than
that in Ad.Null treated cells (Figure 7C). These results
suggest that overexpression of BRG1 may promote theractile SMCs in TAD specimens. (A) Representative images of
al tissues. The percentage of α-SMA positive cells in TAD tissues were
ts represent log10percentage of α-SMAhigh cells against log10BRG1
elation coefficient (r) and the P value indicate the statistical significance
Figure 5 Overexpression of BRG1 induces apoptosis of aortic SMCs. Aortic SMCs were infected with Ad.BRG1 (or Ad.Null) at a MOI of 100.
The expression of BRG1 and its effect on cell apoptosis were detected at 72 hr post-infection. (A, B) The expression level of BRG1 mRNA and
protein was detected by qRT-PCR and western blot and normalized to that of GAPDH and β-actin, respectively. Histogram showed the expression
level of BRG1 mRNA (A) and protein (B) in Ad.BRG1-infected and Ad.Null-infected aortic SMCs. (C) Cells were stained with annexin V-FITC and
propidium iodide (PI). Flow cytometric contour plots showed the percentage of stained cells. Histogram showed the percentage of Annexin
V+/PI− and Annexin V+/PI+ cells of Ad.BRG1-infected and Ad.Null-infected aortic SMCs. Data represent mean ± SEM from 4 independent experiments;
**, P <0.01 by t test.
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synthetic phenotype.
Discussion
Mounting evidence supports the notion that thoracic
aortic dissection (TAD) is the result of biomechanical
weakening of the aortic media [1-3]. Previous studies
revealed that matrix metalloproteinase 2 (MMP2) andFigure 6 Overexpression of BRG1 increases MMP2 and MMP9 express
(or Ad.Null) at a MOI of 100. The expression of MMP2 and MMP9 were detect
to that of GAPDH and β-actin, respectively. Histogram showed the expression
Ad.BRG1-infected and Ad.Null-infected aortic SMCs. Data represent mean ± SEMMP9 overexpression in SMCs might induce extracellular
matrix degradation (especially the elastic fibers), apoptosis
and phenotypic transition of SMCs (from contractile to
synthetic types), and hence is strongly associated with the
development of TAD [6-10]. Here, we show for the first
time that BRG1 is overexpressed in the aortic SMCs of
TAD, and that its overexpression can upregulate
MMP2 and MMP9 expression, induce cell apoptosision in aortic SMCs. Aortic SMCs were infected with Ad.BRG1
ed at 72 hr post-infection by qRT-PCR and western blot and normalized
level of MMP2 and MMP9 at the mRNA (A) and protein (B) level in
M from 4 independent experiments; **, P <0.01 by t test.
Figure 7 Overexpression of BRG1 modulates aortic SMCs from contractile to synthetic phenotype. Aortic SMCs were infected with
Ad.BRG1 (or Ad.Null) at a MOI of 100. (A, B) The expression level of α-SMA mRNA and protein was detected at 72 hr post-infection.by qRT-PCR
and western blot and normalized to that of GAPDH and β-actin, respectively. Histogram showed the expression level of α-SMA mRNA (A) and
protein (B) in Ad.BRG1-infected and Ad.Null-infected aortic SMCs. (C) The percentage of α-SMAhigh aortic SMCs were analyzed by flow cytometry.
Flow cytometric contour plots showed the percentage of stained cells. Histogram showed the percentage of α-SMAhigh cells of Ad.BRG1-infected
and Ad.Null-infected aortic SMCs. Data represent mean ± SEM from 4 independent experiments; *, P <0.05 by t test.**, P <0.01 by t test.
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gest that BRG1 overexpression in aortic SMC contribute
to the development of TAD.
It was reported that BRG1 is essential for the prolifera-
tion and differentiation in a variety of cell types including
SMCs [15,17,23-26]. However, the role of BRG1 in TAD
has not been investigated. In the present study, we first
examine the expression of BRG1 in aortic walls using
immunohistochemical staining. It was found that BRG1
was mainly localized at the nucleus of SMCs in the aortic
media. Through qPCR and western blot analysis of the
adventitia-free aortic walls, we further revealed that the
expression of BRG1 in TAD specimens was significantly
higher than in normal controls, suggesting that BRG1
might be involved in the development of TAD.
Extracellular matrix (ECM) degradation is wildly
regarded as a key pathological process in TAD formation
[6,8]. Matrix metalloproteinase family is a group of protein
enzymes responsible for maintaining the synthetic-lytic
equilibrium of extracellular matrix [27,28], amongst which
MMP2 and MMP9 are members essential for ECM
(especially elastic fibers) degradation [29,30]. Ishii et al.
showed that the expression level of MMP2 and MMP9 in
SMCs of degenerated media was much higher than in
other regions in TAD, suggesting that MMP2 and MMP9
overexpression in aortic SMCs is involved in TAD forma-
tion by promoting extracellular matrix degradation [31].
On the other hand, Ma et al. and Zhang et al. showed that
BRG1 could induce MMP2 and MMP9 overexpression insome human tumor cells, respectively [15,21]. In the
present study, we demonstrated that the expression level
of BRG1 was positively correlated with that of MMP2 and
MMP9 in aortic media of TAD. In addition, using a hu-
man aortic SMC line, we show that BRG1 overexpression
could significantly increase the mRNA and protein
expression of MMP2 and MMP9, indicating BRG1
could promote MMP2 and MMP9 expression in SMCs
probably at the transcriptional level. These results
suggest that BRG1 overexpression may contribute to
the development of TAD via upregulation of MMP2
and MMP9 expression in aortic SMCs and subsequent
enzymatic degradation of the ECM.
Aortic SMCs are responsible for the tensile strength and
elasticity of the aortic wall, which are the characteristic
biomechanical properties of aorta representing its capacity
to withstand stress [5,11,12]. Conceivably, loss of aortic
SMCs would impair the mechanical strength of the vessel
wall, leading to dilation and even rupture of the aortic wall
[5]. It was reported that the number of apoptotic aortic
SMCs in TAD was significantly higher than that in
normal, suggesting that aortic SMCs apoptosis is involved
in the formation of TAD [6,7]. Previous studies showed
that BRG1 overexpression could significantly increase the
apoptotic rate of mesenchymal stem cells and some tumor
cells [19,20]. Recently, Zhang et al. showed that BRG1 was
upregulated in vascular SMC of patients with primary
atherosclerosis and was involved in the pathophysiological
process of atherosclerosis presumably by inducing cell
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is overexpressed in aortic SMC and its level was positively
correlated with the percentage of apoptotic aortic SMCs
in the aortic media of TAD. Using an aortic SMC
line, we further demonstrated that BRG1 overexpression
can significantly induce aortic SMCs apoptosis. Our
results suggested that BRG1 overexpression may promote
the occurrence of TAD by inducing aortic SMCs apoptosis.
SMCs in the normal aorta are mostly quiescent cells
that harbor a unique repertoire of contractile proteins
required for cell functions [33]. It was reported that in
response to vascular injury, the aortic SMCs could
transit from contractile to a synthetic phenotype with
little contractile proteins [34,35]. Inamoto et al. and
Huang et al. independently reported that the proportion
of contractile aortic SMCs in the aortic media of TAD was
significantly lower than in the normal aorta, suggesting
that the transition of aortic SMCs from contractile to
synthetic phenotype may play an important role in aortic
SMCs contractile dysfunction in TAD [36,37]. In the
present study, we found that the level of BRG1 was
positively correlated with the percentage of aortic
SMCs with synthetic phenotype in TAD aortic media.
In cellular experiment with an aortic SMC line, BRG1
overexpression was found to promote the transition
from contractile to synthetic phenotype. The results
imply that overexpression of BRG1 might be involved
in the development of TAD by promoting phenotypic
transition of aortic SMCs. It was reported that BRG1
could up-regulate the stemness genes such as Oct4,
Sox2, Sall4, and maintain the self-renewal capacity in
embryonic stem cells. As we known, the synthetic pheno-
type of aortic SMCs was regarded as the dedifferentiated
cells. In this sense, it would be interesting to see whether
BRG1 promote phenotypic transition of aortic SMCs
through its regulation on the expression of stemness genes
in the future.
However, our study had several limitations that should
be mentioned. Low rate of proliferation is another
important characteristic of contractile phenotype SMCs
other than decreased production of MMPs, increased
expression of SMC-specific contractile genes such as
α-SMA and SM22α. Inflammatory cytokines such as
IL-1β are another important factors regulating phenotype
transition and induce expression of proinflammatory genes
in SMCs. Whether BRG1 regulates SMC proliferation and
the interaction between BRG1 expression and inflammatory
states warrants further investigation. In addition, since the
matrix degradation activity of the MMPs is also regulated
by the presence of naturally present tissue inhibitors
of metalloproteinases (TIMPs), examining the matrix
degradation activity of the MMPs may better reflect the
pathophysiologic role in the development and progression
of the aortic disease than measuring MMP expression.Besides, interactions among MMPs expression, cell phe-
notypes transition and apoptosis would be investigated
in the future. On the other hand, although our clinical
investigation and in vitro cellular experiment suggest that
BRG1 overexpression play roles in the development of
TAD, further studies using appropriate animal models is
still warranted.
Conclusions
In summary, we report here that BRG1 level is significantly
upregulated in aortic SMCs of TAD as compared with the
controls in human samples, and its overexpression in
human aortic SMC line can promote MMP2 and MMP9
expression, apoptosis and phenotypic transition from
contractile to synthetic type. The results suggest that
BRG1 overexpression in aortic SMC may play a role in
the development of TAD. Further experiments in animal
models are warranted to establish the role of BRG1 in the
pathophysiological processes of TAD formation, and
targeting BRG1 might provide a novel therapy in the
treatment of TAD.
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